Markets:

Overview

News

Currencies

International

Treasuries

AbCellera Biologics Inc. - Common Shares (NQ:ABCL)

3.929 -0.061 (-1.54%)

Streaming Delayed Price Updated: 2:22 PM EST, Jan 28, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AbCellera Biologics Inc. - Common Shares

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Why Array Technologies Shares Are Trading Sharply Higher; Here Are 28 Stocks Moving Premarket ↗

November 09, 2022

Gainers NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) shares jumped 32% to $1.65 in pre-market trading. NeuroBo reported closing of $32.3 million underwritten public offering including full exercise of...

Via Benzinga

AbCellera Biologics Inc. (ABCL) Q3 2022 Earnings Call Transcript ↗

November 08, 2022

ABCL earnings call for the period ending September 30, 2022.

Via The Motley Fool

AbCellera Reports Q3 2022 Business Results

November 08, 2022

From AbCellera Biologics Inc.

Via Business Wire

Recap: AbCellera Biologics Q1 Earnings ↗

May 10, 2022

AbCellera Biologics (NASDAQ:ABCL) reported its Q1 earnings results on Tuesday, May 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Via Benzinga

AbCellera to Present at Upcoming Investor Conferences in November

November 04, 2022

From AbCellera Biologics Inc.

Via Business Wire

AbCellera’s First Program with Regeneron in Multi-Target Collaboration Advances in Preclinical Development

November 02, 2022

From AbCellera Biologics Inc.

Via Business Wire

AbCellera to Report Third Quarter 2022 Financial Results on November 8, 2022

October 11, 2022

From AbCellera Biologics Inc.

Via Business Wire

AbCellera Announces Presentation of Data from CD3 T-Cell Engager Platform at SITC 2022

October 05, 2022

From AbCellera Biologics Inc.

Via Business Wire

AbCellera Launches Second Phase of Global Headquarters Expansion to Advance Capabilities for Bringing New Medicines from Target to the Clinic

September 21, 2022

From AbCellera Biologics Inc.

Via Business Wire

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗

September 02, 2022

We're starting off the final trading day of the week with an overview of the biggest pre-market stock movers for Friday!

Via InvestorPlace

Why Invitae Climbed Around 279%; Here Are 98 Biggest Movers From Yesterday ↗

August 11, 2022

Gainers Invitae Corporation (NYSE: NVTA) surged 278.5% to close at $8.63 after the company reported better-than-expected Q2 EPS.

Via Benzinga

Coinbase, Trade Desk, H&R Block And Some Other Big Gainers From Wednesday ↗

August 11, 2022

U.S. stocks closed higher on Wednesday following the release of inflation data. Here is the list of some big stocks moving lower in the previous session.

Via Benzinga

Why Is CarLotz Higher By More Than 30%: Here Are 28 Stocks Moving Premarket ↗

August 10, 2022

Gainers ObsEva SA (NASDAQ: OBSV) shares rose 33.8% to $0.4080 in pre-market trading. ObsEva recently announced a $31 million debt retirement and $11 million debt refinancing.

Via Benzinga

Why Plug Power Is Trading Higher By Around 14%, Here Are 73 Stocks Moving In Wednesday's Mid-Day Session ↗

August 10, 2022

Gainers BioAtla, Inc. (NASDAQ: BCAB) gained 50.1% to $5.42 following Q2 results. Euro Tech Holdings Company Limited (NASDAQ: CLWT) surged 39.5% to $2.0380.

Via Benzinga

AbCellera Reports Q2 2022 Business Results

August 09, 2022

From AbCellera Biologics Inc.

Via Business Wire

AbCellera and Atlas Venture Collaborate to Empower the Development of Impactful Medicines for Patients

August 03, 2022

From AbCellera Biologics Inc.

Via Business Wire

Versant Ventures Collaborates with AbCellera to Accelerate Drug Development for its Portfolio of Biotech Companies

July 27, 2022

From AbCellera Biologics Inc.

Via Business Wire

AbCellera to Report Second Quarter 2022 Financial Results on August 9, 2022

July 12, 2022

From AbCellera Biologics Inc.

Via Business Wire

Lilly to Supply an Additional 150,000 Doses of AbCellera-Discovered Antibody, Bebtelovimab, to the U.S. Government in Ongoing Effort to Provide COVID-19 Treatment Options

June 29, 2022

From AbCellera Biologics Inc.

Via Business Wire

AbCellera Biologics's Return On Capital Employed Insights ↗

June 10, 2022

According to Benzinga Pro, during Q1, AbCellera Biologics (NASDAQ:ABCL) earned $168.57 million, a 181.2% increase from the preceding quarter. AbCellera Biologics also posted a total of $316.58 million...

Via Benzinga

Cramer Shares His Thoughts On Stem, Marvell Technology And More ↗

May 17, 2022

On CNBC’s "Mad Money Lightning Round," Jim Cramer said Marvell Technology Inc (NASDAQ: MRVL) is the "best when it comes to 5G, the best in high-performance computing.

Via Benzinga

What 4 Analyst Ratings Have To Say About AbCellera Biologics ↗

May 11, 2022

Over the past 3 months, 4 analysts have published their opinion on AbCellera Biologics (NASDAQ:ABCL) stock. These analysts are typically employed by large Wall Street banks and tasked with...

Via Benzinga

AbCellera Reports Q1 2022 Business Results

May 10, 2022

From AbCellera Biologics Inc.

Via Business Wire

AbCellera and Empirico Expand Strategic Multi-Target Antibody Discovery Collaboration

May 03, 2022

From AbCellera Biologics Inc.

Via Business Wire

AbCellera to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference on May 2, 2022

April 26, 2022

From AbCellera Biologics Inc.

Via Business Wire

3 Biotech Stocks Under $10 to Add to Your Buy List ↗

April 26, 2022

These biotech stocks to buy are all profitable, which is important for investors looking to reduce their investment risk.

Via InvestorPlace

AbCellera to Report First Quarter 2022 Financial Results on May 10, 2022

April 12, 2022

From AbCellera Biologics Inc.

Via Business Wire

AbCellera Presents Data on T Cell Engager Platform at AACR 2022

April 08, 2022

From AbCellera Biologics Inc.

Via Business Wire

AbCellera Reports Full Year 2021 Business Results

February 24, 2022

From AbCellera Biologics Inc.

Via Business Wire

The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company ↗

February 24, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (...

Via Benzinga

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.